The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 09, 2019

Filed:

Nov. 25, 2015
Applicant:

Catabasis Pharmaceuticals, Inc., Cambridge, MA (US);

Inventors:

Chi B. Vu, Boston, MA (US);

Michael R. Jirousek, Chardon, OH (US);

Assignee:

Catabasis Pharmaceuticals, Inc., Cambridge, MA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/4406 (2006.01); C07D 213/82 (2006.01); A61K 31/105 (2006.01); A61K 31/095 (2006.01); A61K 31/121 (2006.01); A61K 31/195 (2006.01); A61K 45/06 (2006.01); C07C 323/23 (2006.01); A61K 47/54 (2017.01);
U.S. Cl.
CPC ...
A61K 31/105 (2013.01); A61K 31/095 (2013.01); A61K 31/121 (2013.01); A61K 31/195 (2013.01); A61K 31/4406 (2013.01); A61K 45/06 (2013.01); A61K 47/54 (2017.08); C07C 323/23 (2013.01); C07D 213/82 (2013.01);
Abstract

The invention relates to (i) 6-membered heteroaryl substituted fatty acid cystamine conjugates, compositions thereof, methods of treating diseases involving dysregulation of autophagy, such as cystic fibrosis, idiopathic pulmonary fibrosis (IPF), a neurodegenerative disease, inflammatory disease, liver disease, muscle disease, infection and immune disease with this compound, or (ii) a method of treating idiopathic pulmonary fibrosis, mitochondrial diseases, Leigh Syndrome, Diabetes Mellitus and Deafness (DAD), Leber's hereditary optic neuropathy, Neuropathy-ataxia-retinis pigmentosa and ptosis (NARP), myoneurogenic gastrointestinal encephalopathy (MNGlE), myoclonic epilepsy with ragged red fibers (MERRF), or mitochondrial myopathy-encephalomy-opathy-lactic acidosis stroke like symptoms (MELAS), comprising administering to a patient the fatty acid cysteamine conjugate, (4Z, 7Z. 10Z, 13Z, 16Z, 19Z)—N-(2-mercaptoethyl) docosa-4,7,10,13,16,19-hexaenamide or (5Z, 8Z, 11Z, 14Z, 17Z)—N-(2-mercaptoethyl) icosa-5,8,11,14,17-pentaenamide.


Find Patent Forward Citations

Loading…